Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALLRNASDAQ:BNTCNASDAQ:NRBONASDAQ:SCPS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$0.30-3.2%$0.40$0.29▼$154.40$1.93M0.24136,389 shs351,333 shsBNTCBenitec Biopharma$5.25+2.3%$3.96$1.86▼$9.01$13.30M1.0217,631 shs20,970 shsNRBONeuroBo Pharmaceuticals$4.09-5.8%$4.68$2.89▼$7.60$21.06M-0.23263,576 shs34,044 shsSCPSScopus BioPharma$0.00$0.00$0.00▼$0.11$100K1.152,716 shs39,294 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-3.80%-12.24%-23.96%-45.36%-99.58%BNTCBenitec Biopharma+2.34%+3.14%+19.32%+62.54%+48.76%NRBONeuroBo Pharmaceuticals-5.76%-10.70%-14.97%+10.64%-29.99%SCPSScopus BioPharma0.00%+9.09%+20.00%-94.43%-96.07%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.0974 of 5 stars0.03.00.00.02.60.00.0BNTCBenitec Biopharma2.5424 of 5 stars3.55.00.00.03.00.80.0NRBONeuroBo Pharmaceuticals0.1212 of 5 stars0.03.00.00.01.80.00.6SCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity TherapeuticsN/AN/AN/AN/ABNTCBenitec Biopharma3.00Buy$10.0090.48% UpsideNRBONeuroBo PharmaceuticalsN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest BNTC, ALLR, NRBO, and SCPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.001/24/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A($0.93) per shareN/ABNTCBenitec Biopharma$80K169.97N/AN/A$0.12 per share43.75NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$6.84 per shareN/ASCPSScopus BioPharmaN/AN/AN/AN/A($0.33) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/AN/A-91.78%5/9/2024 (Estimated)BNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)NRBONeuroBo Pharmaceuticals-$13.97MN/A0.00N/AN/AN/A-53.17%-39.24%4/4/2024 (Estimated)SCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/A-1,284.70%N/ALatest BNTC, ALLR, NRBO, and SCPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A0.140.14BNTCBenitec Biopharma0.013.623.62NRBONeuroBo PharmaceuticalsN/A5.545.54SCPSScopus BioPharmaN/A0.050.05OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%BNTCBenitec Biopharma52.19%NRBONeuroBo Pharmaceuticals1.37%SCPSScopus BioPharmaN/AInsider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%BNTCBenitec Biopharma4.30%NRBONeuroBo Pharmaceuticals0.79%SCPSScopus BioPharma5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics146.18 million6.17 millionNot OptionableBNTCBenitec Biopharma182.59 million2.48 millionNo DataNRBONeuroBo Pharmaceuticals24.85 million4.81 millionNot OptionableSCPSScopus BioPharma1342.08 million39.94 millionNot OptionableBNTC, ALLR, NRBO, and SCPS HeadlinesSourceHeadlineScopus Biopharma Inc (SCPS)uk.investing.com - February 14 at 10:10 AMArriVent BioPharma Inc AVBPmorningstar.com - February 7 at 12:27 AMScopus BioPharma Inc. (SCPS)finance.yahoo.com - January 31 at 6:43 PM7+ Companies That Had Their IPO in 2020: Best and Worst Performersmsn.com - January 8 at 2:19 PMScopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancerfinance.yahoo.com - November 7 at 9:38 AMScopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancerfinance.yahoo.com - November 2 at 9:23 AMKinnate Biopharma Inc Ordinary Sharesmorningstar.com - July 15 at 7:42 PMThis Biopharma Offspring Is All Grown Upmddionline.com - May 23 at 9:07 PMScopus BioPharma Stock (OTC:SCPS), Insider Trading Activitybenzinga.com - May 16 at 8:53 PMESG Industry Landscape Report: Biopharmamorningstar.com - April 19 at 7:56 PMThese are the roles biopharma companies want to fillsiliconrepublic.com - April 9 at 7:53 AMYS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQbenzinga.com - March 18 at 5:54 PMShort Volatility Alert: Scopus Biopharma Ibenzinga.com - December 16 at 5:42 PMWhy Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarketmsn.com - December 15 at 9:03 AMScopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancerfinance.yahoo.com - November 10 at 12:54 PMScopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Valuefinance.yahoo.com - October 18 at 6:07 PMHedge Funds Go Bottom Fishing in Biopharmainstitutionalinvestor.com - October 6 at 10:20 PMScopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directorsfinance.yahoo.com - May 5 at 9:32 AMScopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summitfinance.yahoo.com - March 22 at 9:00 PMScopus BioPharma Provides Update Following Annual Meeting of Stockholdersfinance.yahoo.com - January 10 at 2:12 PMDR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORSfinance.yahoo.com - January 6 at 8:23 AMScopus Biopharma Inc Shares Approach 52-Week Low - Market Movernasdaq.com - December 28 at 7:37 AMScopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Companyfinance.yahoo.com - December 17 at 10:28 AMHow Will Scopus BioPharma Inc. (NASDAQ: SCPS)’s Current Price Volatility Affect Its Future Potential?marketingsentinel.com - December 8 at 6:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAllarity TherapeuticsNASDAQ:ALLRAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Benitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.NeuroBo PharmaceuticalsNASDAQ:NRBONeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Scopus BioPharmaNASDAQ:SCPSScopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.